TD Asset Management Inc. reduced its stake in Pfizer Inc. (NYSE:PFE) by 13.9% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 5,806,513 shares of the biopharmaceutical company’s stock after selling 936,279 shares during the period. TD Asset Management Inc. owned 0.10% of Pfizer worth $204,447,000 at the end of the most recent reporting period.
Other large investors also recently made changes to their positions in the company. Stelac Advisory Services LLC acquired a new stake in Pfizer during the second quarter worth $110,000. Catamount Wealth Management increased its stake in Pfizer by 14.2% in the first quarter. Catamount Wealth Management now owns 4,395 shares of the biopharmaceutical company’s stock worth $130,000 after buying an additional 545 shares in the last quarter. Commonwealth Financial Services LLC increased its stake in Pfizer by 5.5% in the second quarter. Commonwealth Financial Services LLC now owns 4,023 shares of the biopharmaceutical company’s stock worth $142,000 after buying an additional 210 shares in the last quarter. Stuart Chaussee & Associates Inc. increased its stake in Pfizer by 64.3% in the second quarter. Stuart Chaussee & Associates Inc. now owns 5,430 shares of the biopharmaceutical company’s stock worth $193,000 after buying an additional 2,125 shares in the last quarter. Finally, Financial Management Professionals Inc. increased its stake in Pfizer by 21.9% in the second quarter. Financial Management Professionals Inc. now owns 5,517 shares of the biopharmaceutical company’s stock worth $193,000 after buying an additional 993 shares in the last quarter. Institutional investors and hedge funds own 69.66% of the company’s stock.
Shares of Pfizer Inc. (NYSE:PFE) traded down 0.31% during trading on Friday, hitting $32.66. The company had a trading volume of 15,569,339 shares. The stock has a market capitalization of $198.10 billion, a price-to-earnings ratio of 28.95 and a beta of 0.86. The stock has a 50-day moving average of $34.02 and a 200 day moving average of $34.27. Pfizer Inc. has a 12-month low of $28.25 and a 12-month high of $37.39.
Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, August 2nd. The biopharmaceutical company reported $0.64 EPS for the quarter, beating the consensus estimate of $0.62 by $0.02. The firm earned $13.10 billion during the quarter, compared to the consensus estimate of $13.01 billion. Pfizer had a return on equity of 23.37% and a net margin of 14.88%. The business’s quarterly revenue was up 10.9% on a year-over-year basis. During the same period last year, the company earned $0.56 earnings per share. On average, analysts predict that Pfizer Inc. will post $2.46 EPS for the current fiscal year.
The company also recently announced a quarterly dividend, which will be paid on Thursday, December 1st. Shareholders of record on Friday, November 11th will be given a $0.30 dividend. The ex-dividend date of this dividend is Tuesday, November 8th. This represents a $1.20 annualized dividend and a yield of 3.67%. Pfizer’s dividend payout ratio is presently 95.24%.
A number of equities research analysts have weighed in on the stock. Argus reiterated a “buy” rating and set a $39.00 price target on shares of Pfizer in a research note on Sunday, August 28th. Vetr upgraded shares of Pfizer from a “buy” rating to a “strong-buy” rating and set a $37.94 price target on the stock in a research note on Monday, June 27th. Barclays PLC reiterated an “equal weight” rating and set a $34.00 price target on shares of Pfizer in a research note on Tuesday, August 2nd. Jefferies Group decreased their price target on shares of Pfizer from $42.00 to $40.00 and set a “buy” rating on the stock in a research note on Monday, June 20th. Finally, Zacks Investment Research cut Pfizer from a “buy” rating to a “hold” rating in a report on Wednesday, July 20th. Eleven research analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has given a strong buy rating to the stock. Pfizer presently has an average rating of “Buy” and a consensus price target of $38.59.
Pfizer Company Profile
Pfizer Inc is a research-based global biopharmaceutical company. The Company is engaged in discovering, developing and manufacturing of healthcare products. Its portfolio includes medicines, vaccines and medical devices, as well as consumer healthcare products. Its products include Prevnar/Prevenar 13, Lyrica, Enbrel, Lipitor, Viagra, Sutent, BeneFIX, Genotropin, ReFacto, Xyntha and Enbrel.
Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.